Ethnicity and pharmacogenetics

Mount Sinai Journal of Medicine

Volumn 63, Issue 5-6, 1996, Pages 285-290

  Smith, Michael W ^a   Mendoza, Ricardo P ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Bldg B 4 South ^*

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; PSYCHOTROPIC AGENT;

DIET; DRUG METABOLISM; DRUG PROTEIN BINDING; ENVIRONMENT; ETHNOLOGY; GENOTYPE; HUMAN; PHARMACOGENETICS; PHENOTYPE; REVIEW;

BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; ETHNIC GROUPS; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE; PSYCHOTROPIC DRUGS; UNITED STATES;

EID: 0029851756     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (75)

1. Gonzalez F. The molecular biology of cytochrome P450s. Pharmacol Rev 1989; 40:243-288.
2. Gonzalez F, Nebert D. Evolution of the P450 gene super-family: animal-plant "warfare" molecular drive and human genetic differences in drug oxidation. Trends Genet 1990; 6:182-186.
3. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991; 12:102-107.
4. Meyer U, Zanger U, Grant D, Blum M. Genetic polymorphisms of drug metabolism. Adv Drug Res 1990; 19:12-17.
5. Bertilsson L, Eichelbaum M, Mellstrom B. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sci 1980; 27:1673-1677.
6. Bertilsson L, Aberg-Wistedt A. The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine. Br J Clin Pharmacol 1983; 15:388-390.
7. Clark W, Brater D, Johnson A. Goth's medical pharmacology. 12th ed. St. Louis: The C.V. Mosby Company, 1988.
8. Kalow W. Race and therapeutic drug response. N Engl J Med 1989; 320:588-589.
9. Shen W, Lin K. Cytochrome P-450 monooxygenases and interactions of psychotropic drugs. Int J Psychiatry Med 1990; 21:21-30.
10. Yue QY, Hasselstrom J, Svensson JO, Sawe J. Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br J Clin Pharmacol 1991; 31:635-642.
11. Bertilsson L, Mellstorm B, Sjoqvist F, Martensson B, Asberg M. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications, Lancet 1981; 111:560-561.
12. Shah RR, Oates NS, Idle JR, et al. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J 1982; 284:295-299.
13. Sjoqvist F, Bertilsson L. Slow hydroxylation of tricyclic antidepressants: relationship to polymorphic drug oxidation. In: Kalow W, Goedde HW, Agarwal DP, editors. Ethnic differences in reaction to drugs and xenobiotics. New York: NY: Alan R. Liss Inc., 1986: 169-188.
14. Dahl-Puustinen ML, Liden A, Alm C. Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation in human beings. Clin Pharmacol Ther 1989; 6:78-81.
15. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man, Pharmacogenetics 1993; 3:61-70.
16. Wood A, Zhou H. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20:1-24.
17. Zhou H, Kashakji R, Siolberstein D, Wilkinson G, Wood A. Altered sensitivity to and clearance of propranolol in men of Chinese decent as compared with American white. N Engl J Med 1989; 320:565-570.
18. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984; 26:753-759.
19. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Clin Pharmacol Ther 1989; 43:53-76.
20. Smith CAD, Gough AC, Leigh PH, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339:1375-1377.
21. Fleming CA, Kaisary A, Wilkinson GR, et al. The ability to 4-hydroxylate debrisoquine is related to recurrence of bladder cancer. Pharmacogenetics 1992; 2:128-134.
22. Kaisary A, Smith P, Jacqz E, et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987; 47: 5488-5493.
23. Hirvonen A, Husgafvel-Pursiainen, Antila S, et al. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 1993; 3:19-27.
24. Jorge LF, Arias TD, Inaba T, Jackson PR. Unimodal distribution of the metabolic ratio for debrisoquine in Cuna Amerindians of Panama. Br J Clin Pharmacol 1990; 30:281-285.
25. Mahgoub A, Idle JR, Smith RL. A population of familial study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. Xenobiotica 1979; 9:51-56.
26. Islam SI, Idle JR, Smith RL. The polymorphic 4-hydroxylation of debrisoquine in a Saudi-Arab population. Xenobiotica 1980; 10:819-825.
27. Lou Y, Ying L, Bertilsson L, Sjoqvist. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Clin Pharmacol Ther 1987; 15:443-450.
28. Lee EJ, Nam YP, Hee GN. Oxidation phenotyping in Chinese and Malay populations. Clin Exp Pharmacol Physiol 1988; 15:889-891.
29. Xu X, Jian GW. Debrisoquine hydroxylation and sulfamethazine acetylation in a Chinese population. Chung-Kuo Yao Li Hsueh Pao (Acta Pharmacol Sin) 1990; 11:387-388.
30. Du Y, Lou Y. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population. Chung-Kuo Yao Li Hsueh Pao (Acta Pharmacol Sin) 1990; 11:7-10.
31. Silver B, Poland R, Lin K. Ethnicity and the pharmacology of tricyclic antidepressants. In: Lin PK, Poland R, Nakasaki G, editors. Psychopharmacology and psychobiology of ethnicity. Washington DC: American Psychiatric Press, 1993.
32. Masimirembwa CM, Johansson I, Hasler JAL, Magnus. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993; 3: 275-280.
33. Meyer U. Molecular genetics and the future of pharmacogenetics. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press, 1992.
34. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993; 53: 410-418.
35. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P4502D6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 1990; 265:17206-17214.
36. Ingelman-Sundberg M, Johansson I, Persson I, et al. Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer. Pharmacogenetics 1992; 2:264-271.
37. Relling MV, Cherrie J, Schell MJ, et al. Lower prevalence of the debrisoquine oxidative poor metabolizer phenotype in American blacks versus white subjects. Clin Pharmacol Ther 1991; 50:308-313.
38. Baumann P, Eap C. Alpha-acid glycoprotein genetics. Biochemistry, physiological functions and pharmacology. New York: Alan R. Liss, 1988.
39. Kremer J, Wilting J, Janssen L. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988; 40:1-45.
40. Fukuma Y, Kashimimura S, Umetsu K, et al. Genetic variation of alpha-2-HS-glycoprotein in the Kyushu district of Japan: description of three new rare variants. Hum Hered 1990; 40:49-51.
41. Juneja R, Weitkamp L, Straitil A. Further studies of the plasma, αβ-glycoprotein polymorphism: two new alleles and allele frequencies in Caucasians and in American Blacks. Hum Hered 1988; 38:267-272.
42. Umetsu K, Yuasa I, Nishimura H. Genetic polymorphisms of orosomucoid and alpha-2-HS-glycoprotein in a Philippine population. Hum Hered 1988; 38:287-290.
43. Routledge P. The plasma protein binding of basic drugs. Br J Clin Pharmacol 1986; 22:499-506.
44. Levy R, Moreland T. Rationale for monitoring free drug levels. Clin Pharmacokinet 1984; S1:1-9.
45. Baumann P, Eap C. Plasma monitoring of antidepressants: clinical relevance of the pharmacogenetics of metabolism and of acid glycoprotein binding. Biol Psychiatry 1991; 29:75-95.
46. Crabtree B, Jann M, Pits W. Alpha acid glycoprotein levels in patients with schizophrenia: effect of treatment with haloperidol. Biol Psychiatry 1991; 29:43A-48A.
47. Mendoza R, Smith M, Poland R, et al. Ethnic psychopharmacology the Hispanic and Native American perspective. Psychopharmacol Bull 1991; 27:449-461.
48. Bertilsson L, Dahl M, Edqqvist B, et al. Genetic regulation of the disposition of psychotropic drugs.In: Meltzer HY, Nerozzi D, editors. Current practices and future developments in the pharmacotherapy of mental disorders. Amsterdam: Elsevier Science Publishers, 1991: 73-80.
49. Bronsen K, Sindrup SH, Skjelbo E, et al. Role of genetic polymorphism in psychopharmacology, an update. Psychopharmacol Ser 1993; 10:199-211.
50. Lin KM, Poland RE. Ethnicity, culture, and psychopharmacology. In: Bloom FE, Kupfer DI, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995.
51. Jones B, Runikis A. Interaction of ginseng with phenelzine. J Clin Psychopharmacol 1987; 201-202.
52. Liu GT. Effects of some compounds isolated from Chinese medicinal herbs of hepatic microsomal cytochrome P-450 and their potential biological consequences. Drug Metab Rev 1991; 23:439-465.
53. Shader R, Greenblatt D. Bees, ginseng and MAOIs revisited (editorial). J Clin Psychopharmacol 1988; 8:325.
54. Anderson K, Conney A, Kappas A. Nutritional influences on chemical biotransformations in humans. Nutr Rev 1982; 40:161-169.
55. Anderson KE. Influences of diet and nutrition on clinical pharmacokinetics. Clin Pharmacokinet 1988; 14:325-346.
56. Anderson KE, McCleery RB, Vesell ES, Vickers FF, Kappas A. Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects. Hepatology 1991; 13:941-946.
57. Anderson KE, Kappas A. Dietary regulation of cytochrome P450. Annu Rev Nutr 1991; 11;141-167.
58. Branch R, Salih S, Homeida M. Racial differences in drug metabolizing ability: a study with antipyrine in the Sudan. Clin Pharmacol Ther 1978; 24:283-286.
59. Brosen K, Skjelbo E. Fluoxetine and norfluoxetine are potent inhibitors of P4011D6-the source of the sparteine/debrisoquine oxidation polymorphism (letter). Br J Clin Pharmacol 1991; 32:136-137.
60. Llerena A, Herraiz AG, Cobaleda J, et al. Debrisoquine and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents. Clin Pharmacol Ther 1993; 54:606-611.
61. Sigusch H, Hippius M, Henschel L, et al. Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation. Pharmazie 1994; 49:522-524.
62. Smith M, Lin K, Mendoza R. "Non-Biological" issues affecting psychopharmacotherapy: cultural considerations. In Lin K, Poland R, Nakasaki G, editors, Psychopharmacology and psychobiology of ethnicity. Washington: American Psychiatric Press, 1993.
63. Fraser H, Mucklow J, Bulpitt C, et al. Environmental factors affecting antipyrine metabolism in London factor and office workers. Br J Clin Pharmacol 1979; 7: 237-243.
64. Dollery C, Faser H, Mucklow J. Contribution of environmental factors to variability in human drug metabolism. Drug Metab Rev 1979; 9:207-220.
65. Desai NK, Sheth UK, Mucklow JC. Antipyrine clearance in Indian villagers. Br J Clin Pharmacol 1980; 9:387-394.
66. Okey A. Enzyme induction in the cytochrome P-450 system. New York: Pergamon Press, 1992.
67. Murray M, Ready G. Selectivity in the inhibition of mammalian cytochromes P-450 by chemical agents. Pharmacol Rev 1990; 42:2-101.
68. Yamahara J, Kobayashi M, Matsuda H, et al. Anticholinergic action of Swertia Japonica and an active constituent. J Ethnopharmacol 1991; 33:31-35.
69. Egashira T, Sudo S, Murayarna F, et al. Effects of kamikihi-to, a Chinese traditional medicine, on various cholinergic biochemical markers in the brain of aged rats. Nippon Yakurigaku Zasshi (Folia Pharmacol Jpn) 1991; 98:273-281.
70. Carbajal D, Casaco A, Arruzazabala L, et al. Pharmacological screening of plant decoctions commonly used in Cuban folk medicine. J Ethnopharmacol 1991; 33:21-24.
71. Lewis WH, Kennelly EJ, Bass GN, et al. Ritualistic use of the holly ilex guayusa by Amazonian Jivaro Indians. J Ethnopharmacol 1991; 33;25-30.
72. Kleinman A. Patients and healers in the context of culture. Berkeley: University of California, 1980.
73. Vermeer DE, Farrell RE. Nigerian geophagical clay: a traditional antidiarrheal pharmaceutical. Science 1985; 227:634-636.
74. Westermeyer J. Psychiatric care of migrants: a clinical guide. Washington DC: American Psychiatric Press, 1989.
75. Brosen K, Hansen JG, Nielsen KK, et al. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993; 344:349-355.